74 results about "Pseudomonas aeruginosa Infections" patented technology

Method and apparatus for using computer controlled, fiber-coupled laser delivery of treatment specific wavelength, intensity and duration of UV irradiation to control bacterial, fungal, viral and mold infections in bodily cavities, fluids and external applications. The method of treatment is focused on DNA breakdown beyond repair by natural DNA repair mechanisms of the pathogen, with less than damaging doses to tissues being treated, thus avoiding mutagenicity and carcinogenicity. The minimal intensity and duration and exposure area of any given surface of tissue to be treated is to be pre-determined by tissue and pathogen testing to optimize the therapeutic ratio. External applications include specifically Trichophyton Rubrum (toenail fungus) through the nail and Pseudomonas Aeruginosa infections in burns and elsewhere.

The present invention relates to methods for detecting P aeruginosa infection and bacterial burden in the lungs of patients who are at risk for P. aeruginosa infections, especially including patients with Cystic Fibrosis (CF). The present method provides numerous tests (breath, blood, urine) which are readily administered to a patient that will sensitively and specifically detect the presence and extent of lung infection P. aeruginosa (both mucoid and non-mucoid), and allow monitoring of bacterial load as a parameter in monitoring treatment.

Improved antibodies are provided selected from human, dual-specific, chimeric or humanized antibodies, wherein said human chimeric and humanized antibodies specifically bind to flagellin type A or type B of P. aeruginosa, and said dual-specific antibodies specifically binds to flagella type A and type B of Pseudomonas aeruginosa, and said antibodies are protective against infection caused by P. aeruginosa. These antibodies as well as pharmaceutical composition comprising them are useful for the treatment of indications caused by P. aeruginosa infection.

The present invention relates to methods for detecting P aeruginosa infection and bacterial burden in the lungs of patients who are at risk for P. aeruginosa infections, especially including patients with Cystic Fibrosis (CF). The present method provides numerous tests (breath, blood, urine) which are readily administered to a patient that will sensitively and specifically detect the presence and extent of lung infection P. aeruginosa (both mucoid and non-mucoid), and allow monitoring of bacterial load as a parameter in monitoring treatment.

Method and apparatus for using computer controlled, fiber-coupled laser delivery of treatment specific wavelength, intensity and duration of UV irradiation to control bacterial, fungal, viral and mold infections in bodily cavities, fluids and external applications. The method of treatment is focused on DNA breakdown beyond repair by natural DNA repair mechanisms of the pathogen, with less than damaging doses to tissues being treated, thus avoiding mutagenicity and carcinogenicity. The minimal intensity and duration and exposure area of any given surface of tissue to be treated is to be pre-determined by tissue and pathogen testing to optimize the therapeutic ratio. External applications include specifically Trichophyton Rubrum (toenail fungus) through the nail and Pseudomonas Aeruginosa infections in burns and elsewhere.

The present invention provides improved pharmaceutical compositions and methods of treating or preventing development of bacteremia associated with Pseudomonas aeruginosa infections, where the method comprises administering an antibiotic and an anti-PcrV antibody.

The present invention relates to a pseudomonas aeruginosa phage and an application thereof, and particularly discloses the phage capable of entering blood and the application thereof. The phage singlebody is the pseudomonas aeruginosa phage with a Latin name P. Aeruginosaphage, and named as ASP11, and has a broad-spectrum bactericidal ability against pseudomonas aeruginosa. The phage ASP11 is preserved in China General Microbiological Culture Collection Center, a preservation date is September 26, 2018 and a preservation number is CGMCC NO.16395. Both in vivo and in vitro tests show that thephage has a strong cleavage effect on the pseudomonas aeruginosa and provides an effective method for prevention and treatment of pseudomonas aeruginosa infected diseases.

The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

The invention belongs to the technical field of preparing compounds, and relates to a compound separated and extracted from marine penicillium and application thereof. The compound is used for preventing and treating in-vitra and in-vivo pseudomonas aeruginosa infection of people or animals, and the chemical formula of the compound which is obtained by fermenting the marine penicillium and has the effect of inhibiting quorum sensing of pseudomonas aeruginosa is 4,6-dimethyl-7-[(1R,2E,4aS,7R,8R,8aR)-1,2.4a,5,6,7,8,8a-octahydro-7-hydroxyl-2-(3-hydroxyl-2-oxygen-propylene)-3,6,8-trimethyl-1-naphthyl]-,(2E,4E,6E)-heptantriene acid, and the molecular formula of the compound is C25H34O5; the compound does not inhibit the growth of the wild type pseudomonas aeruginosa; the quorum-sensing inhibition effect of the compound is concentration-dependent, and is gradually strengthened with the increase of the concentration; virulence factors controlled by the quorum sensing of the pseudomonas aeruginosa can be inhibited; and the compound also has the advantages of readily available raw materials, simple and easily controlled preparation process, obvious sensing inhibition effect and prominent social benefits.

The invention provides a pCasPA / pACRISPR dual-plasmid system. The pCasPA / pACRISPR dual-plasmid system is characterized by comprising at least one of a pCasPA plasmid and a pACRISPR plasmid, the pCasPAplasmid can express Cas9 protein and a lambda-Red recombinant system, and the pACRISPR plasmid can express sgRNA. The pCasPA / pACRISPR dual-plasmid system can efficiently and rapidly knock out the genes of various strains of pseudomonas aeruginosa, efficiently and rapidly conducts gene insertion on the genomes of various strains of pseudomonas aeruginosa. The technology has the broad application prospect on the aspects such as the treatment of pseudomonas aeruginosa infection, drug target discovery, drug development and physiological research of the pseudomonas aeruginosa.

The invention relates to a method for establishing a pseudomonas aeruginosa infectious pneumonia animal model. The method comprises the following steps: 1) deeply anesthetizing a mouse by adopting isoflurane; and 2) dripping nose of the mouse with pseudomonas aeruginosa, so that a pseudomonas aeruginosa infectious pneumonia model is established. The method provided by the invention has the advantages that the mouse can be effectively infected, and the pseudomonas aeruginosa pneumonia model is successfully established; and the mouse model after infection is stable and can be applied to evaluation of vaccines and research of protective mechanisms.

The invention discloses a tricyclic quinolone derivative or its salt and hydrate with a novel structure and a non-basic substituent substituted C10 peripheral group. Activity determination of the compound by various strains proves that the compound has antibacterial activity on a variety of sensitive strains and resistant strains, can be used for treatment of infection diseases caused by Gram negative and positive bacteria, and is especially suitable for treatment of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa infection.

The present invention is drawn to conjugates and vaccine compositions comprising a Pseudomonas flagellin or an antigenic fragment or derivative thereof linked to one or more Klebsiella surface polysaccharide antigens, such as Klebsiella pneumoniae O5 polysaccharide from serovars O1, O2a, O2a,c, O3, O4, O5, O7, O8 and 012. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions.

The present invention relates to novel diagnostic, prognostic and therapeutic reagents for infection of an animal subject such as a human by Pseudomonas aeruginosa, and conditions associated with such infections, such as, for example, an acute clinical exacerbation in a cystic fibrosis (CF) subject. In particular, the present invention relates to methods for diagnosing / prognosing an infection by P. aeruginosa in a subject comprising detecting the presence or amount of one or more proteins of P. aeruginosa or a fragment or epitope thereof or an antibody thereto in a sample from the subject.

The present invention relates to polypeptides of Pseudomonas aeruginosa which may be used to prevent, diagnose and / or treat Pseudomonas aeruginosa infection.

The present invention relates to assays, kits and oligonucleotides for the detection of Pseudomonas aeruginosa for a fast, sensitive and reliable detection of Pseudomonas aeruginosa in a species- and serotype-specific manner. In particular, the present invention provides an assay for the serotype-specific detection of Pseudomonas aeruginosa, a kit for the serotype-specific detection of Pseudomonas aeruginosa, as well as oligonucleotides useful in such assay or kit. The present invention further relates to the use of Pseudomonas aeruginosa serotype specific antibodies for serotype specific treatment of Pseudomonas aeruginosa infection in a patient detected for said specific Pseudomonas aeruginosa serotype with such an assay or kit.

Improved antibodies are provided selected from human, dual-specific, chimeric or humanized antibodies, wherein said human chimeric and humanized antibodies specifically bind to flagellin type A or type B of P. aeruginosa, and said dual-specific antibodies specifically binds to flagella type A and type B of Pseudomonas aeruginosa, and said antibodies are protective against infection caused by P. aeruginosa. These antibodies as well as pharmaceutical composition comprising them are useful for the treatment of indications caused by P. aeruginosa infection.

The invention relates to application of 3-methyladenine in preparation of a medicine for preventing acute pneumonia induced by pseudomonas aeruginosa, and belongs to the technical field of biomedicine. Experimental research shows that before pseudomonas aeruginosa infection, the survival rate of experimental animals can be increased by using 3-methyladenine, and meanwhile, host tissue damage caused by excessive inflammatory immune response is avoided along with pathology reduction and reduction of inflammatory cytokines and in-lung bacteria load; and the increasing drug resistance of bacteria to existing antibiotics due to improper use of the antibiotics can be avoided, and the application prospect is wide.

An object is to provide: a protein antigen or a peptide antigen usable as a vaccine composition which has an ability to practically prevent or treat a Pseudomonas aeruginosa infection, and which can cope with the diversity of clinical isolates derived from patients with a Pseudomonas aeruginosa infection; and an antibody directed against the antigen. The present invention provides a protein antigen or a peptide antigen and an antibody directed against these, which are for use in diagnosis, prevention, or treatment of a disease associated with Pseudomonas aeruginosa. According to the present invention, a protein or a peptide derived from a Pseudomonas aeruginosa-outer membrane protein PA4710, and an antibody directed against these are provided, which are for use in diagnosis, prevention, or treatment of a disease associated with Pseudomonas aeruginosa.

The invention discloses a pseudomonas aeruginosa OprF-VP22 gene, the application of the gene for making vaccines for controlling pseudomonas aeruginosa infection, and a pseudomonas aeruginosa DNA vaccine containing the gene.

The present invention is drawn to conjugates and vaccine compositions comprising a Pseudomonas flagellin or an antigenic fragment or derivative thereof linked to one or more Klebsiella surface polysaccharide antigens, such as Klebsiella pneumoniae O polysaccharide from serovars O1, O2a, O2a,c, O3, O4, O5, O7, O8 and O12. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions.

The invention discloses application of 2,6-bis(2-benzimidazolyl) pyridine in preparation of a carbapenem-resistant pseudomonas aeruginosa infection drug. Through circular dichroism, fluorescent real-time quantitative PCR and other methods, it is found that 2, 6-bis (2-benzimidazolyl) pyridine can form a G-quadruplex structure with a core sequence of a MexA gene in pseudomonas aeruginosa, thereby inhibiting expression of the MexA gene. A susceptibility testing verifies that 2, 6-bis (2-benzimidazolyl) pyridine can reduce the drug resistance of carbapenem-resistant pseudomonas aeruginosa to meropenem. When the usage amount of the 2, 6-bis (2-benzimidazolyl) pyridine is 5 <mu>M, the minimum inhibitory concentration of the carbapenem-resistant pseudomonas aeruginosa strain can be reduced to 2<mu> g / ml, and the effect of treating carbapenem-resistant pseudomonas aeruginosa infection by using meropenem is achieved.

A combination of an antibody and other therapeutic that work together in vivo against a pathogenic microbe. The combination can include the antibody with an antibiotic, and / or a therapeutic against adisease. The combination can attack the pathogenic microbe with an efficiency more than either of the components alone, with a synergistic effect, or an effect moderated by one or more modes of actionnot existing with administration of either the antibody or therapeutic alone.

Provided is an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Provided are a monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient. Concretely, monoclonal antibody of the present invention has excellent inhibiting activity on cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the monoclonal antibody of the present invention has high affinity with PcrV.

The present invention relates to a nucleic acid aptamer ETA01 of Pseudomonas aeruginosa exotoxin A and its application. The sequence of the nucleic acid aptamer ETA01 includes: 5'-TGCAACTCCAACTAACCATGTGTTCAT CTGAGGGTGGTCTTCGCA-3'. The nucleic acid aptamer ETA01 of the present invention can bind to Pseudomonas aeruginosa exotoxin A with high affinity and high specificity, and use the nucleic acid aptamer ETA01 as the recognition element of Pseudomonas aeruginosa exotoxin A to establish Pseudomonas aeruginosa The detection method of bacterial exotoxin A, the preparation of detection reagents, and the development of exotoxin A antagonistic drugs can be used in the diagnosis and treatment of Pseudomonas aeruginosa infection and the research on the biological function of Pseudomonas aeruginosa exotoxin A. The method has the advantages of simplicity, rapidity and good characteristics.

Disclosed herein are mono and bispecific DNA antibodies (DMAbs) targeting Pseudomonas aeruginosa. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering theDMAbs to the subject. The disclosure also provides a method of preventing and / or treating Pseudomonas aeruginosa infection in a subject using said composition and method of generation.

The invention provides a fusion protein for preventing pseudomonas aeruginosa infection. The fusion protei comprises a first peptide fragment, a second peptide fragment and a third peptide fragment which are linearly connected and combined; the amino acid sequence of the first peptide fragment is SEQ ID NO:94; the amino acid sequence of the second peptide fragment is SEQ ID NO:95; and the amino acid sequence of the third peptide fragment is SEQ ID NO: 96. The invention further provides a recombinant gene for encoding the fusion protein and application of the fusion protein in preventing the pseudomonas aeruginosa infection. The fusion protein disclosed by the invention can effectively prevent infection of various serotypes of pseudomonas aeruginosa.

Proteins derived from Pseudomonas aeruginosa are antigenic and are of use in the treatment, prophylaxis and diagnosis of P. aeruginosa infection.

Provided is a novel prophylactic and / or therapeutic agent for Pseudomonas aeruginosa infection. It was found that a bacterium belonging to the genus Enterococcus can prevent and / or treat Pseudomonas aeruginosa infection. The prophylactic and / or therapeutic agent for Pseudomonas aeruginosa infection, comprising a bacterium belonging to the genus Enterococcus. A medicine for prevention and / or treatment of Pseudomonas aeruginosa infection, comprising a bacterium belonging to the genus Enterococcus. A food for prevention and / or treatment of Pseudomonas aeruginosa infection, comprising a bacterium belonging to the genus Enterococcus.

The invention discloses an application of PA4608 protein as a target in preparing antibacterial drugs. By constructing a PA4608 (mapZ) site mutant strain mapz_R13A and a mapZ whole gene knockout mutant and by utilizing a nematode-quick killing infection model, a scratch cell model and a mouse abdominal infection model for study, the invention first puts forwards that the c-di-GMP binding site of PA4608 protein plays an important regulatory role in pseudomonas aeruginosa infection process, puts forwards that the site is a key site for the pathogenicity of the pseudomonas aeruginosa, and furtherputs forwards a new target, namely a c-di-GMP receptor PA4608 used for preventing and / or treating the pseudomonas aeruginosa. The invention provides an important theoretical basis for the developmentof new antibacterial drugs, especially for the design of new antibacterial drugs based on c-di-GMP receptor induction mechanism, provides an important theoretical reference for the prevention and clinical treatment of pseudomonas aeruginosa infection, and has important practical significance.